Nautilus Biotechnology (NAUT) Q4 2025 earnings summary

Executive summary

• Achieved significant technical and commercial milestones in Q4 2025, including the public unveiling of the Voyager instrument and the early launch of the Iterative Mapping Early Access Program, progressing toward a late 2026 commercial launch.

• Early access program initiated with strong interest from academic, nonprofit, and biopharma sectors, focusing on tau proteoform assays and expanding to additional targets such as alpha-synuclein and oncology.

• Collaborations with leading institutions like the Buck Institute, Allen Institute, Michael J. Fox Foundation, and Weill Cornell Medicine Qatar provided robust external validation, grant funding, and Parkinson's disease research projects.

• Platform demonstrated unique biological insights, particularly in neurodegeneration, with plans to expand into oncology and other disease areas.

• Platform showcased at major scientific conferences, supporting commercial launch preparations and generating strong interest from the research community.

Financial highlights

• Q4 2025 operating expenses were $15.4 million, down 23% year-over-year; full-year 2025 operating expenses were $66.8 million, down 18%.

• Research and development expenses for 2025 were $41.1 million, a 19% decrease from 2024, driven by lower lab supplies, equipment, and headcount.

• General and administrative expenses for 2025 were $25.7 million, down 17% year-over-year, mainly due to reduced stock-based compensation and professional services.

• Net loss for Q4 2025 was $13.8 million, compared to $17.6 million in Q4 2024; full-year net loss was $59.0 million, improved from $70.8 million in 2024.

• Ended Q4 2025 with $156.1 million in cash equivalents and investments; 2025 cash burn was $50.2 million, down from $57.8 million in 2024.

Outlook and guidance

• Operating expenses expected to increase by 15%-20% in 2026 as investments ramp up for platform development and commercial readiness.

• Anticipated 2026 cash burn of $65–$70 million, with cash runway projected through 2027.

• No material revenue expected from Early Access Program in 2026; modest services revenue expected, with primary revenue ramp beginning in 2027 as instrument shipments commence.

• Commercial launch of Voyager platform planned for late 2026, with instrument installations at customer sites starting in early 2027.